AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12777909
Drug: Murine monoclonal
RxNorm normalized name: 131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I
DrugBank: Apamistamab iodine I-131 (DB16748)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Murine monoclonal antibody to the human intercellular adhesion molecule-1 (enlimomab)
Trial: 10700898
Drug: UFT oral
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT oral administration for one year at 3-4 capsules daily
Trial: 10700898
Drug: CDDP i.p.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDDP i.p. administration of 70 mg/m2 at the time of resective surgery
Trial: 8251021
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (15 ml per day containing 3.1 g of omega-3 fatty acids)
Trial: 3693871
Drug: Nitrazepam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam (2.5 mg)
Trial: 26687902
Drug: Escalated dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated dose radiotherapy (54 Gy/36f/12 days to 57.6 Gy, 61.2 Gy, and 64.8 Gy)
Trial: 26687902
Drug: Escalated dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated dose radiotherapy
Trial: 23001893
Drug: Concurrent palliative
RxNorm normalized name: Various pain palliation radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent palliative care
Trial: 18371200
Drug: Likelihood of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Likelihood of reporting harm in the abstract when funded by drug companies
Trial: 12810489
Drug: Rivastigmine 6‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 6‐ to 12‐mg/d
Trial: 8779365
Drug: Ephedrine 0.1
RxNorm normalized name: Primatene with ephedrine 0.125 MG/ACTUAT Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 0.1 mg.kg‐1
Trial: 2022674
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate 4% during daily dressing changes
Trial: 30451718
Drug: Patient education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient education by a clinical pharmacist on correct patch administration
Trial: 16801302
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (exact dosage and duration not specified)
Trial: 12766829
Drug: Estriol-containing vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol-containing vaginal pessary (0.5 mg estriol) twice weekly
Trial: 12766829
Drug: Nitrofurantoin macrocrystal
RxNorm normalized name: Nitrofurantoin macrocrystal
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin macrocrystal (100 mg) once daily
Trial: 1498532
Drug: gu chi
RxNorm normalized name: Gu
DrugBank: Guanidine (DB00536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gu chi wan (tooth firming pills) 4 mg twice daily for 3‐6 months combined with spiramycin 0.2 four times daily for 5 days and routine periodontal treatment
Trial: 1498532
Drug: spiramycin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spiramycin 0.2 four times daily for 5 days combined with routine periodontal treatment
Trial: 1498532
Drug: gu chi
RxNorm normalized name: Gu
DrugBank: Guanidine (DB00536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gu chi wan (tooth firming pills)
Trial: 3701513
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy (experimental group)
Trial: 3701513
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy (iron-deficient not anemic group, n = 22)
Trial: 28646940
Drug: Intradetrusor injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradetrusor injection of botulinum toxin type A (BTX‐A) 100 U
Trial: 28646940
Drug: Intradetrusor injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradetrusor injection of botulinum toxin type A (BTX‐A)
Trial: 27163420
Drug: Diltiazem infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem infusion (2.5 microgram/kg/min)
Trial: 27163420
Drug: No diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No diltiazem infusion
Trial: 11841884
Drug: Diltiazem infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem infusion
Trial: 15093845
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac tromethamine (0.5 mg/kg, max 30 mg)
Trial: 9048403
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg/day continued prophylaxis, N = 90
Trial: 27084247
Drug: High-dose CVVHDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CVVHDF (80mL/kg/h)
Trial: 27084247
Drug: Conventional-dose CVVHDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose CVVHDF (40mL/kg/h)
Trial: 25026897
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: 3 cycles of epirubicin 110 mg/m2 followed by 3 cycles of paclitaxel 200 mg/m2 followed by 3 cycles of intensified CMF
Trial: 25026897
Drug: Arm B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: 3 cycles of epirubicin followed by 3 cycles of CMF, then 9 weekly cycles of docetaxel 35 mg/m2
Trial: 25026897
Drug: Arm C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm C: 9 weekly cycles of paclitaxel 80 mg/m2
Trial: 16831228
Drug: Low basic
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low basic antibody titre against influenza
Trial: 10703660
Drug: Supra-gingival oral
RxNorm normalized name: Supra Sulfa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supra-gingival oral irrigation plus routine oral hygiene (ROH) for 14 days
Trial: 10703660
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral hygiene (ROH) for 14 days
Trial: 10703660
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral hygiene for 14 days
Trial: 26625939
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy protocol with supervised usage of adaptive devices (n=20)
Trial: 26625939
Drug: Conventional occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional occupational therapy (n=20)
Trial: 22369176
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment containing a seaweed-derived oligosaccharide complexed with 0.1% zinc pyrrolidone
Trial: 10408405
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) 1000 mg m‐2 intravenous (i.v.) weekly for 3 weeks out of every 4 and 5‐fluorouracil (5‐FU) 600 mg m‐2 bolus i.v. weekly for 3 weeks out of every 4
Trial: 7551201
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with high doses of Parietaria extract (cumulative dose of 105 BU)
Trial: 1763422
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training for remembering names and faces (treatment duration: one month, twice weekly)
Trial: 29847188
Drug: Combined MLD
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined MLD and vibrotherapy treatment
Trial: 22415479
Drug: Suboptimal 25OHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboptimal 25OHD (<72 nmol/l)
Trial: 22415479
Drug: 25OHD, insulin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25OHD, insulin, CRP, and leptin levels as continuous variables
Trial: 19329013
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL normal saline (control group)
Trial: 12174106
Drug: Azathioprine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 2.5 mg kg(‐1) day(‐1)
Trial: 9400430
Drug: 1 gm.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gm. mycophenolate mofetil twice daily
Trial: 9400430
Drug: 1.5 gm.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 gm. mycophenolate mofetil twice daily
Trial: 729378
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive with synthetic estrogen (ethinyl estradiol)
Trial: 729378
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive with natural estrogens (micronized estradiol and estriol)
Trial: 28437539
Drug: Low-dose valganciclovir
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose valganciclovir hydrochloride (n=46)
Trial: 21157026
Drug: Galantamine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (16 to 24 mg/day)
Trial: 19692371
Drug: Intravitreal pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal pegaptanib (IVP) 0.3 mg every 6 weeks for 30 weeks
Trial: 14724039
Drug: 50‐mg oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50‐mg oral naltrexone
Trial: 11431296
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (12.5 mg zinc sulphate daily for six days a week for six months)
Trial: 9741901
Drug: New sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New sustained-release formulation of amoxicillin (500 mg)
Trial: 9741901
Drug: Conventional gelatin
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional gelatin capsule of amoxicillin (500 mg)
Trial: 8285810
Drug: Comparison drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison drug
Trial: 29604311
Drug: Formulations containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations containing silicone particles
Trial: 29604311
Drug: Formulations containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations containing Microsponge® particles (control)
Trial: 20863241
Drug: Surface preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface preparation with 37% phosphoric acid for 30 s
Trial: 20863241
Drug: Surface preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface preparation with 0.5‐W Er,Cr:YSGG laser for 6 s
Trial: 18353086
Drug: No surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No surface preparation
Trial: 20863241
Drug: Conventional bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional bleaching procedure (without surface preparation)
Trial: 18851795
Drug: Amifostine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (500 mg/m2)
Trial: 18851795
Drug: Glutamine (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (1500 mg/m2)
Trial: 3306904
Drug: Loperamide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (4 mg nocte)
Trial: 29354971
Drug: Flipping moxibustion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flipping moxibustion of Hui medicine combined with western medication
Trial: 29354971
Drug: Simple western
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple western medication (oral methotrexate and sulfasalazine)
Trial: 25701866
Drug: Daily proguanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily proguanil
Trial: 22476119
Drug: Ciprofloxacin 200
RxNorm normalized name: ciprofloxacin 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 200 mg bid for 7 days
Trial: 22476119
Drug: Ciprofloxacin 200
RxNorm normalized name: ciprofloxacin 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 200 mg bid for 7 days (excluding Child-Pugh A and patients without ascites)
Trial: 18236372
Drug: Basiliximab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (20 mg immediately following surgery and four days postoperatively)
Trial: 18236372
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CSA, adapted to blood-trough level 120-150 ng/mL for six months)
Trial: 12679436
Drug: Ghrelin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin (1.0 micro g/kg iv)
Trial: 9364537
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m2, intravenous infusion for 1 hour once every 3 weeks)
Trial: 9364537
Drug: Doxorubicin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (75 mg/m2, intravenous infusion for 15 to 20 minutes once every 3 weeks)
Trial: 31561652
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (20 mL) only (group B)
Trial: 31561652
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% + 10 mg morphine (group BM10)
Trial: 31561652
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% + 15 mg morphine (group BM15)
Trial: 27364096
Drug: Diphtheria, tetanus,
RxNorm normalized name: Diphtheria, Tetanus, Poliomyelitis adsorbed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria, tetanus, and polio booster vaccines
Trial: 22472339
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (0.4 mg daily)
Trial: 18727841
Drug: r‐hFSH and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r‐hFSH and r‐hLH (all doses)
Trial: 10665496
Drug: CP-122,288 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-122,288 (doses between 3.125 and 312.5 microg orally)
Trial: 9313057
Drug: Ciprofloxacin administered
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin administered intravenously (200 to 400 mg) or orally (500 to 750 mg) twice a day for 6 to 21 days
Trial: 8317647
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of ginger
Trial: 31969155
Drug: Maternal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal treatment with primaquine
Trial: 26472297
Drug: Sham TENS
RxNorm normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham TENS treatment sessions (control group)
Trial: 23186260
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 5% i.u. infusion (140 ml)
Trial: 23186260
Drug: Saline i.u.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline i.u. infusion (140 ml)
Trial: 20693158
Drug: gemfibrozil, niacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemfibrozil, niacin, and cholestyramine in combination
Trial: 18325911
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (IV) - received staff asthma training, advice on asthma policy, emergency beta(2)-agonist inhaler with spacer, and asthma lesson
Trial: 9377615
Drug: Hydrocortisone buteprate
RxNorm normalized name: Hydrocortisone buteprate
DrugBank: Hydrocortisone probutate (DB14543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone buteprate 0.1% cream
Trial: 24442048
Drug: Nutraceutical (Q10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical (Q10 coenzyme, Krill-oil, lipoic acid, resveratrol, Vitis vinifera seed oil, vitamin E, selenium) in addition to etanercept therapy
Trial: 24442048
Drug: Etanercept therapy
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept therapy alone
Trial: 18502911
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (intended six months of continued conservative treatment)
Trial: 16574893
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg torcetrapib once daily for 4 weeks
Trial: 16574893
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg torcetrapib twice daily for an additional 4 weeks (nonatorvastatin group)
Trial: 16574893
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg torcetrapib on a background of atorvastatin
Trial: 11789169
Drug: 1000 ml
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 ml gastrointestinal dialysate (non‐absorbed mannitol solution) orally 2‐3 times a day
Trial: 11789169
Drug: XQN 5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XQN 5‐10 tablets 3 times per day combined with 1000 ml gastrointestinal dialysate (non‐absorbed mannitol solution) orally 2‐3 times a day
Trial: 11789169
Drug: Coated aldehyde
RxNorm normalized name: lauryl aldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated aldehyde oxystarch 5‐10 g, 3 times a day
Trial: 8455235
Drug: Intravesical bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical bacillus Calmette-Guerin (BCG) administration
Trial: 3523636
Drug: Ornidazole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole (2.5 g/m2, administered orally, two times weekly for 3 weeks, total dose 15 g/m2)
Trial: 3523636
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered orally, two times weekly for 3 weeks)
Trial: 23410186
Drug: Phenylephrine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (50 to 100 μg)
Trial: 23410186
Drug: Ephedrine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (5 to 10 mg)
Trial: 17118491
Drug: Chewing gum
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gum (sugar-free or regular) for 15 min hourly after lunch
Trial: 15789977
Drug: Oral‐B Indicator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B Indicator
Trial: 12518488
Drug: Oral‐B CrossAction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B CrossAction
Trial: 11169936
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg/m2 on Day 1) plus Vinorelbine (25 mg/m2 on Days 1 and 8, every 3 weeks for a minimum of 3 cycles)
Trial: 11169936
Drug: Vinorelbine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (30 mg/m2/week for a minimum of 9 weeks)
Trial: 26275653
Drug: Chlorella vulgaris
RxNorm normalized name: CHLORELLA VULGARIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella vulgaris extract (CVE) 1800 mg/day
Trial: 26275653
Drug: Standard antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antidepressant therapy alone (Control)
Trial: 23219636
Drug: High-dose, high-repetition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose, high-repetition medical exercise therapy
Trial: 23219636
Drug: Low-dose, low-repetition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose, low-repetition exercise therapy
Trial: 21986283
Drug: LCI699 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCI699 1.0 mg once daily
Trial: 21986283
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of LCI699
Trial: 17326594
Drug: AVINZA (morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVINZA (morphine sulfate extended-release capsules) once a day
Trial: 17326594
Drug: OxyContin (oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OxyContin (oxycodone controlled-release tablets) twice a day
Trial: 12718385
Drug: Doxorubicin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (30 mg)
Trial: 12718385
Drug: Mitoxantrone (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (14 mg)
Trial: 9548208
Drug: Captopril (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5 mg daily)
Trial: 11855793
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg daily)
Trial: 1606094
Drug: 10-mg intravenous
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10-mg intravenous metoclopramide
Trial: 31164067
Drug: 60 hours
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 hours of therapy
Trial: 31164067
Drug: 0 hours
RxNorm normalized name: nicotine 0.583 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 hours of therapy
Trial: 31164067
Drug: 15 hours
RxNorm normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 15 hours of therapy
Trial: 31164067
Drug: 30 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 hours of therapy